Several findings suggest that rhACE2 may be a promising drug for those with intolerance to classic renin-angiotensin system inhibitors (RAS inhibitors) or in diseases where circulating angiotensin II is elevated.Infused rhACE2 has been evaluated in clinical trials for the treatment of acute respiratory distress syndrome.